A detailed history of Price T Rowe Associates Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,252,749 shares of BCRX stock, worth $16.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,252,749
Previous 1,948,984 15.59%
Holding current value
$16.9 Million
Previous $12 Million 42.14%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.41 - $8.69 $1.95 Million - $2.64 Million
303,765 Added 15.59%
2,252,749 $17.1 Million
Q2 2024

Aug 14, 2024

BUY
$4.13 - $6.79 $7.51 Million - $12.3 Million
1,818,209 Added 1390.33%
1,948,984 $12 Million
Q1 2024

May 15, 2024

BUY
$4.89 - $7.65 $83,574 - $130,746
17,091 Added 15.03%
130,775 $665,000
Q4 2023

Feb 14, 2024

BUY
$4.98 - $6.77 $46,657 - $63,428
9,369 Added 8.98%
113,684 $681,000
Q3 2023

Nov 14, 2023

BUY
$6.71 - $7.92 $56,853 - $67,106
8,473 Added 8.84%
104,315 $739,000
Q2 2023

Aug 14, 2023

BUY
$6.96 - $8.81 $59,257 - $75,008
8,514 Added 9.75%
95,842 $675,000
Q1 2023

May 15, 2023

BUY
$7.94 - $11.84 $27,821 - $41,487
3,504 Added 4.18%
87,328 $729,000
Q4 2022

Feb 14, 2023

BUY
$10.5 - $14.2 $22,102 - $29,891
2,105 Added 2.58%
83,824 $962,000
Q3 2022

Nov 14, 2022

BUY
$10.79 - $14.81 $60,132 - $82,536
5,573 Added 7.32%
81,719 $1.03 Million
Q2 2022

Aug 15, 2022

SELL
$7.89 - $17.88 $38,369 - $86,950
-4,863 Reduced 6.0%
76,146 $806,000
Q1 2022

May 16, 2022

SELL
$11.56 - $19.76 $79,024 - $135,079
-6,836 Reduced 7.78%
81,009 $1.32 Million
Q4 2021

Feb 14, 2022

SELL
$11.18 - $15.46 $67,214 - $92,945
-6,012 Reduced 6.41%
87,845 $1.22 Million
Q3 2021

Nov 15, 2021

BUY
$14.21 - $17.65 $24,029 - $29,846
1,691 Added 1.83%
93,857 $1.35 Million
Q2 2021

Aug 16, 2021

SELL
$9.5 - $17.24 $36,328 - $65,925
-3,824 Reduced 3.98%
92,166 $1.46 Million
Q1 2021

May 17, 2021

BUY
$7.37 - $13.61 $63,713 - $117,658
8,645 Added 9.9%
95,990 $976,000
Q4 2020

Feb 16, 2021

BUY
$3.37 - $8.61 $294,352 - $752,040
87,345 New
87,345 $651,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.39B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.